Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

5 terminated/withdrawn out of 20 trials

Success Rate

37.5%

-49.0% vs industry average

Late-Stage Pipeline

15%

3 trials in Phase 3/4

Results Transparency

167%

5 of 3 completed trials have results

Key Signals

8 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

10(52.6%)

Phase 2

6(31.6%)

Phase 3

3(15.8%)

19Total

Phase 1(10)

Phase 2(6)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials

NCT06414590Phase 2Recruiting

Neoadjuvant Tebentafusp for Uveal Melanoma

Role: collaborator

NCT07493122Phase 1Not Yet Recruiting

Study of IMC-S118AI in Type 1 Diabetes

Role: lead

NCT03070392Phase 2Completed

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Role: lead

NCT04262466Phase 1Active Not Recruiting

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Role: lead

NCT06246149Phase 3Recruiting

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Role: collaborator

NCT06070012Phase 2Recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Role: collaborator

NCT05549297Phase 3Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Role: lead

NCT06112314Phase 3Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Role: lead

NCT07156136Phase 1Recruiting

Study of IMC-P115C in Advanced PRAME-Positive Cancers

Role: lead

NCT06627244Phase 2Recruiting

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Role: collaborator

NCT06840119Phase 1Recruiting

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Role: lead

NCT05315258Phase 2Active Not Recruiting

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Role: collaborator

NCT03973333Phase 1Withdrawn

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Role: lead

NCT05867056Phase 1Withdrawn

Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

Role: lead

NCT02535078Phase 1Withdrawn

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Role: lead

NCT02570308Phase 1Completed

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Role: lead

NCT03515551Phase 1Terminated

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Role: lead

NCT04960891Unknown

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

Role: lead

NCT02889861Phase 2Terminated

IMCgp100-401 Rollover Study

Role: lead

NCT01211262Phase 1Completed

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Role: lead

All 20 trials loaded